Leading ASF Defence: Next-Gen Vaccines for Animal Welfare, Global Economy, and Rural Wellbeing 💉🐖 🇪🇺 Funded by @HorizonEU programme.
- Tweets24
- Following59
- Followers24
- Likes19
ALT Leading the Fight Against ASF: VAX4ASF Objectives (1 of 5)
ALT On November 5th, the Annual Consortium Meeting for the European VAX4ASF project was held, where a comprehensive report on the achievements of the first year was presented, along with discussions on the main lines of research for the coming year. The event brought together the project’s 17 partners from various fields, including scientific research, animal welfare, veterinary medicine, and epidemiology, all collaborating closely to develop innovative solutions to combat African Swine Fever (ASF), a devastating disease that affects global swine populations.
ALT Progress and Key Achievements of VAX4ASF’s First Year In its inaugural year, the VAX4ASF project, formally known as “New Technologies for African Swine Fever”, has laid a strong research foundation, focusing on two innovative approaches for limited replication vaccines aimed at overcoming previous barriers to effective African Swine Fever (ASF) prevention. These vaccine strategies, though still in experimental stages, are evolving well with further advanced testing estimated in the coming year.
ALT Expectations for the Project’s Second Year In the coming year, VAX4ASF will focus on advancing the vaccine prototypes through testing phases, conducting safety and efficacy studies, and strengthening its collaboration network with key players in the livestock and animal health industries. These efforts will adhere to strict research protocols to ensure the developed solutions are effective, safe, and aligned with European and international regulations. The European Commission remains committed to supporting VAX4ASF as part of its efforts to enhance food safety and protect biodiversity and animal welfare in Europe and regions affected by ASF.
ALT The European project VAX4ASF — New Technologies for African Swine Fever (ASF) — aims to develop advanced technologies to provide an effective and safe response to ASF virus. Led by the biopharmaceutical company HIPRA and supported by the European Union under the Horizon Europe program, VAX4ASF brings together research centres from various countries, universities, and technology sector companies working in a coordinated effort to not only mitigate ASF’s impact but also provide tools for eradicating the disease in affected areas.
